Premium
High‐efficiency electrotransfection of human primary hematopoietic stem sells
Author(s) -
Li L. H.,
Mccarthy P.,
Hui S. W.
Publication year - 2001
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.00-0447fje
Subject(s) - haematopoiesis , stem cell , transfection , genetic enhancement , ex vivo , hematopoietic stem cell , microbiology and biotechnology , biology , cell culture , in vivo , gene , biochemistry , genetics
A major obstacle to gene transfer into hematopoietic stem cells, a key step for many gene therapy and tissue replacement applications, is its low efficiency. High cell mortality is responsible for the low efficiency of electrotransfection when this technique is applied to certain ‘refractory’ cell types such as hematopoietic stem cells. Using human primary CD‐34 + cells from peripheral blood as a model, we found that transfection‐induced apoptosis and, to a lesser extent, postpulse colloidal‐osmotic swelling are two main factors for the poor transfection of these cells. By applying caspase inhibitors (B‐D‐Fluomethyl Ketone and Z‐VAD‐FMK) to reduce apoptosis, and by using the postpulse pelleting method to suppress colloidal‐osmotic swelling, we achieved a transfection efficiency of ~20%, regardless of the presence of cytokines in the suspension medium. This effort brings the iex vivo /i electrotransfection efficiency within the reach of therapeutic applications.